EMA Withdrawn: Helixate NexGen (octocog alfa) — Bayer AG

View source ↗

Summary

EMA has withdrawn Helixate NexGen (octocog alfa) from the market, with the therapeutic area being Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Helixate NexGen (Factor VIII, recombinant)

Snippet

Status: Withdrawn. Therapeutic area: Hemophilia A. MAH: Bayer AG. Decision date: 16/11/2017